ICD-10: D56.5. Short Description: Hemoglobin E-beta thalassemia. Long Description: Hemoglobin E-beta thalassemia. Version 2019 of the ICD-10-CM diagnosis code D56.5. Valid for Submission. The code D56.5 is valid for submission for HIPAA-covered transactions.
The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code D58.2 might also be used to specify conditions or terms like acquired hemoglobinopathy, central cyanosis, hemoglobin c disease, hemoglobin c trait, hemoglobin d disease, hemoglobin d trait, etc
Sickle-cell trait. D57.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM D57.3 became effective on October 1, 2019.
D58.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM D58.2 became effective on October 1, 2018. This is the American ICD-10-CM version of D58.2 - other international versions of ICD-10 D58.2 may differ.
D58.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM D58.2 became effective on October 1, 2019. This is the American ICD-10-CM version of D58.2 - other international versions of ICD-10 D58.2 may differ. A type 1 excludes note is a pure excludes.
Hemoglobin C trait (AC) is an inherited condition which affects the hemoglobin in your red blood cells. • Hemoglobin is a protein in red blood cells. The job of hemoglobin is. to carry oxygen throughout the body.
Hemoglobin C is an abnormal type of hemoglobin, the protein in red blood cells that carries oxygen. It is a type of hemoglobinopathy. The disease is caused by a problem with a gene called beta globin. The disease most often occurs in African Americans.
Hemoglobin C/beta-thalassemia disease causes moderate destruction of the red blood cells. Persons who are affected may have a more severe anemia and the spleen may be enlarged.
The disorder is often found during newborn screening blood tests. Blood tests for hemoglobin C disease include: Complete blood count (CBC). This checks the red and white blood cells, blood clotting cells (platelets), and sometimes, young red blood cells (reticulocytes).
Hemoglobin C disease is not a form of sickle cell disease. People who have hemoglobin C disease have red blood cells that contain mostly hemoglobin C. Too much hemoglobin C can reduce the number and size of red blood cells in your body, causing mild anemia.
What is hemoglobin C disease? Hemoglobin C disease is a blood disorder that can cause fatigue, weakness, and anemia. It occurs when a person inherits two copies of hemoglobin C genes from their parents. Hemoglobin is an iron-rich protein that transports oxygen throughout the body.
Hemoglobin C is caused due to mutation in the beta-globin chain in which glutamate (acidic) is replaced by lysine (basic) in the sixth position of the beta-globin chain. This mutation makes Hb C less soluble than Hb A, forming hexagonal crystals (HbC crystals as seen in the peripheral smear).
Most individuals with hemoglobin C/ thalassemia have a mild anemia marked by a low MCV and target cells.
Unlike sickle cell disease, Hb C does not cause linear intracellular polymerization of red cells that encounter intravascular areas of low oxygen tension. Thus, while there is evidence for reduced red cell deformability associated with the Hb C variant (see below), vaso-occlusion does not occur.
Sickle-hemoglobin C disease is a milder form of sickle cell anemia. Hemoglobin is the part of the red blood cells that carries oxygen through the body. The most common (“normal”) form is called hemoglobin A. Your child's red blood cells contain two different hemoglobins, called hemoglobin S and hemoglobin C.
Treatment. Although hemoglobin C disease is a chronic condition, it usually doesn't require any treatment. The anemia that develops is mild and rarely interferes with everyday life. Neither children nor adults need any special therapy, vitamins, or iron supplements to treat hemoglobin C disease.
Hemoglobin C trait (HbAC) is clinically silent. Hemoglobin C disease (HbCC) is also a mild disorder, and most people do not have any symptoms. But some patients may experience mild hemolytic anemia and hence may complain of symptoms like fatigue, lightheadedness, weakness, and paleness of the skin.
Hemoglobin C disease is caused by a genetic change in the gene that provides instructions to the body to make hemoglobin. This genetic change causes a change in the shape of the red blood cells so that oxygen isn't carried as well throughout the body.
Is it safe for people with sickle cell trait to donate blood? Yes. If you have sickle cell trait, you are still are able to donate blood. There is no evidence to suggest that donating blood causes any additional risk of harm or injury to people with sickle cell trait.
Those who carry hemoglobin C, considered an abnormal variation, may develop hemoglobin C disease. This blood disorder develops because the red blood cells do not contain enough water and are too rigid. They break down earlier than they should, leaving too few in the blood and leading to mild anemia.
Hemoglobins characterized by structural alterations within the molecule. The alteration can be either absence, addition or substitution of one or more amino acids in the globin part of the molecule at selected positions in the polypeptide chains.
A disease characterized by compensated hemolysis with a normal hemoglobin level or a mild to moderate anemia. There may be intermittent abdominal discomfort, splenomegaly, and slight jaundice. A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.
The 2022 edition of ICD-10-CM D58.2 became effective on October 1, 2021.
Sickle cell-hemoglobin c disease. Clinical Information. One of the sickle cell disorders characterized by the presence of both hemoglobin s and hemoglobin c. It is similar to, but less severe than sickle cell anemia.
The 2022 edition of ICD-10-CM D57.20 became effective on October 1, 2021.
HEMOGLOBINOPATHIES- . a group of inherited disorders characterized by structural alterations within the hemoglobin molecule.
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)
D58.2 is a billable diagnosis code used to specify a medical diagnosis of other hemoglobinopathies. The code D58.2 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have.
The 2022 edition of ICD-10-CM D57.3 became effective on October 1, 2021.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
The 2022 edition of ICD-10-CM O99.019 became effective on October 1, 2021 .
O99- Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium
O99.1 Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pre gnancy, childbirth and the puerperium. O99.11 Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy.
The 2022 edition of ICD-10-CM D56.1 became effective on October 1, 2021.
There is retardation of hemoglobin a synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, cooley's anemia, mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin a synthesis is absent.